Fjarde AP Fonden Fourth Swedish National Pension Fund Raises Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 13.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 20,992 shares of the company’s stock after buying an additional 2,500 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in IDEXX Laboratories were worth $8,679,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of IDXX. Howard Capital Management Inc. increased its stake in shares of IDEXX Laboratories by 3.0% in the fourth quarter. Howard Capital Management Inc. now owns 2,304 shares of the company’s stock worth $953,000 after acquiring an additional 67 shares during the period. Olympiad Research LP acquired a new stake in IDEXX Laboratories during the 4th quarter worth about $209,000. Bradley Foster & Sargent Inc. CT grew its position in IDEXX Laboratories by 2,000.7% during the 4th quarter. Bradley Foster & Sargent Inc. CT now owns 88,713 shares of the company’s stock worth $36,678,000 after purchasing an additional 84,490 shares during the period. Suncoast Equity Management lifted its holdings in shares of IDEXX Laboratories by 11.6% in the 4th quarter. Suncoast Equity Management now owns 1,524 shares of the company’s stock valued at $630,000 after buying an additional 158 shares during the period. Finally, Tandem Investment Advisors Inc. purchased a new stake in shares of IDEXX Laboratories in the fourth quarter worth about $1,598,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the transaction, the director now owns 905 shares of the company’s stock, valued at $380,498.20. This represents a 27.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 13,330 shares of company stock valued at $6,161,276. 2.11% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts recently weighed in on IDXX shares. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Barclays lifted their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Morgan Stanley lowered their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, February 5th. Finally, Piper Sandler upped their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $533.75.

IDEXX Laboratories Stock Up 2.4 %

Shares of NASDAQ IDXX opened at $463.66 on Tuesday. The firm has a market cap of $37.97 billion, a price-to-earnings ratio of 43.45, a price-to-earnings-growth ratio of 3.41 and a beta of 1.37. The company’s 50-day simple moving average is $432.58 and its 200-day simple moving average is $452.04. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $583.39.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.